Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660

Talk to a Data Expert

Have a question? We'll get back to you promptly.